{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T21:00:57Z","timestamp":1771275657142,"version":"3.50.1"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","award":["PCF Challenge Award"],"award-info":[{"award-number":["PCF Challenge Award"]}],"id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1038\/s41391-025-00937-0","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T12:59:48Z","timestamp":1736341188000},"page":"202-204","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of clinical risk stratification to determine benefit from long-term versus short-term androgen deprivation in high-risk localized prostate cancer"],"prefix":"10.1038","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7466-4702","authenticated-orcid":false,"given":"Praful","family":"Ravi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanling","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silke","family":"Gillessen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertrand","family":"Tombal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5973-4741","authenticated-orcid":false,"given":"Daniel E.","family":"Spratt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul L.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher J.","family":"Sweeney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,8]]},"reference":[{"key":"937_CR1","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/S1470-2045(21)00705-1","volume":"23","author":"AU Kishan","year":"2022","unstructured":"Kishan AU, Sun Y, Hartman H, Pisansky TM, Bolla M, Neven A, et al. Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis. Lancet Oncol. 2022;23:304\u201316.","journal-title":"Lancet Oncol"},{"key":"937_CR2","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.ijrobp.2022.12.035","volume":"116","author":"PL Nguyen","year":"2023","unstructured":"Nguyen PL, Huang HR, Spratt DE, Davicioni E, Sandler HM, Shipley WU, et al. Analysis of a Biopsy-Based Genomic Classifier in High-Risk Prostate Cancer: Meta-Analysis of the NRG Oncology\/Radiation Therapy Oncology Group 9202, 9413, and 9902 Phase 3 Randomized Trials. Int J Radiat Oncol Biol Phys. 2023;116:521\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"937_CR3","doi-asserted-by":"publisher","unstructured":"Armstrong AJ, Liu VYT, Selvaraju RR, Chen E, Simko J, DeVries S, et al. Development and validation of an AI-derived digital pathology-based biomarker to predict benefit of long-term androgen deprivation therapy with radiotherapy in men with localized high-risk prostate cancer across multiple phase III NRG\/RTOG trials. J Clin Oncol. 2023;41. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.5001.","DOI":"10.1200\/JCO.2023.41.16_suppl.5001"},{"key":"937_CR4","doi-asserted-by":"publisher","first-page":"EVIDoa2300023","DOI":"10.1056\/EVIDoa2300023","volume":"2","author":"DE Spratt","year":"2023","unstructured":"Spratt DE, Tang S, Sun Y, Huang HC, Chen E, Mohamad O, et al. Artificial Intelligence Predictive Model for Hormone Therapy Use in Prostate Cancer. NEJM Evid. 2023;2:EVIDoa2300023.","journal-title":"NEJM Evid"},{"key":"937_CR5","unstructured":"Ravi P, Xie W, Buyse M, Halabi S, Kantoff PW, Sartor O, et al. Refining Risk Stratification of High-risk and Locoregional Prostate Cancer: A Pooled Analysis of Randomized Trials. Eur Urol. 2024. https:\/\/pubmed.ncbi.nlm.nih.gov\/38777647\/."},{"key":"937_CR6","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1056\/NEJMoa0810095","volume":"360","author":"M Bolla","year":"2009","unstructured":"Bolla M, de Reijke TM, Van Tienhoven G, Van den Bergh AC, Oddens J, Poortmans PM, et al. Duration of androgen suppression in the treatment of prostate cancer. N. Engl J Med. 2009;360:2516\u201327.","journal-title":"N. Engl J Med"},{"key":"937_CR7","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.ijrobp.2017.02.004","volume":"98","author":"CAF Lawton","year":"2017","unstructured":"Lawton CAF, Lin X, Hanks GE, Lepor H, Grignon DJ, Brereton HD, et al. Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202. Int J Radiat Oncol Biol Phys. 2017;98:296\u2013303.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"937_CR8","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S1470-2045(18)30757-5","volume":"20","author":"JW Denham","year":"2019","unstructured":"Denham JW, Joseph D, Lamb DS, Spry NA, Duchesne G, Matthews J, et al. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial. Lancet Oncol. 2019;20:267\u201381.","journal-title":"Lancet Oncol"},{"key":"937_CR9","doi-asserted-by":"publisher","first-page":"140","DOI":"10.6004\/jnccn.2024.0019","volume":"22","author":"EM Schaeffer","year":"2024","unstructured":"Schaeffer EM, Srinivas S, Adra N, An Y, Bitting R, Chapin B, et al. NCCN Guidelines(R) Insights: Prostate Cancer, Version 3.2024. J Natl Compr Canc Netw. 2024;22:140\u201350.","journal-title":"J Natl Compr Canc Netw"},{"key":"937_CR10","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(22)00190-5","volume":"23","author":"A Zapatero","year":"2022","unstructured":"Zapatero A, Guerrero A, Maldonado X, Alvarez A, San-Segundo CG, Rodriguez MAC, et al. High-dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01\/05): 10-year results of a phase 3 randomised, controlled trial. Lancet Oncol. 2022;23:671\u201381.","journal-title":"Lancet Oncol"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-00937-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-00937-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-00937-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T20:02:10Z","timestamp":1771272130000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-00937-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,8]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["937"],"URL":"https:\/\/doi.org\/10.1038\/s41391-025-00937-0","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,8]]},"assertion":[{"value":"5 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"PR\u2014Research funding to institution from Bayer, Lilly, Telix, Blue Earth Diagnostics, Lantheus, Novartis, Advisory board - Bayer; WX\u2014Consulting Role: Convergent Therapeutics, PCCTC; SG\u2014Personal honoraria for participation in\n                      advisory boards\n                      from Amgen, MSD;\n                      other honoraria\n                      from Radio-televisione Svizzera Italiana (RSI), German-speaking European School of Oncology (DESO);\n                      invited speaker\n                      for ESMO, Swiss group for Clinical Cancer Research (SAKK), Swiss Academy of Multidisciplinary oncology (SAMO), Orikata academy research group,\n                      Speaker\u2019s bureau\n                      for Janssen Cilag;\n                      travel grant\n                      from ProteoMEdiX and AstraZeneca; Institutional honoraria for participation in\n                      advisory boards or in Independent Data Monitoring Committees and Steering Committees\n                      from AAA International, Amgen, AstraZeneca, Astellas Pharma, Bayer, Bristol-Myers Squibb, DAIICHI Sankyo, Janssen, Modra Pharmaceuticals, MSD, Myriad Genetic, Novartis, Orion, Pfizer, Roche, Telixpharma, Tolermo Pharmaceutcials;\n                      invited speaker\n                      for Swiss group for Clinical Cancer Research (SAKK), Cold Spring Harbor Laboratory, ASCO GU;\n                      other honoraria\n                      from PeerVoice, Silvio Grasso Consulting, WebMD-Medscape; Patent royalties and other intellectual property for a research method for biomarker WO2009138392; DES\u2014Personal fees: Astellas, AstraZeneca, Bayer, Boston Scientific, GSK, Janssen, Novartis, Pfizer; PLN\u2014research funding paid to institution: Janssen, Astellas, Bayer; Consulting: Boston Scientific, Janssen, Bayer, Novartis, Nanocan; Stock or Other Ownership: Nanocan, Stratagen Bio, Reversal Therapeutics; CJS\u2014research funding paid to institution by Janssen, Astellas, Sanofi, Bayer; Patents, Consulting, or Advisory Role: Sanofi, Janssen, Astellas, Bayer, Genentech\/Roche, Pfizer, Lilly; Hengrui; CellCentric, PointBiopharma; Royalties and other Intellectual Property: Parthenolide (Indiana University); dimethylamino parthenolide (Leuchemix); Exelixis: Abiraterone plus cabozantinib combination; FRAS1 SNP and tristetraprolin as biomarkers of lethal prostate cancer; Stock or Other Ownership: Leuchemix. All other authors declare to relevant conflicts.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}